bottom-lin consid stock
disloc coverag upgrad overweight
reflect view compani growth opportun
diagnost breast health underappreci current
posit molecular view holx molecular
diagnost busi sale
organ sale growth brighten past year risk
major custom renew rear-view competitor
roch abbott qiagen/neumodx advanc
slowli expect bolster
competit defens softwar autom link
multipl instrument well fda test clearanc
increment women health assay covid anyth think
covid crisi could enhanc opportun holx molecular
franchis mid-term import autom infecti
diseas test becom promin final recent spoke
kol histor skeptic tone
chang believ holx molecular busi gain
share next sever year echo mani reason
weve list
surgic strike us matur market leadership posit
profit review competit landscap holx
surgic busi well physician channel check bolster
view retain market leadership posit
surgic tool endometri ablat fibroid remov
covid pandem consequ cancel elect procedur
dampen near-term demand believ much demand
recaptur later period physician spoke
expect recaptur cancel procedur
answer consist well med-tech team survey elect
procedur trend physician across medic specialti
estim reduc reflect covid headwind price target
reduc lower peer multipl weve reduc forecast
reflect impact covid pandem lower diagnost
test procedur volum tighter hospit capital-expenditure weve
assum materi disrupt busi may-end
ep goe ep
weve reduc price target reflect
lower comp group multipl lower estim
continu follow page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
non-gaap ep exclud intang acquir amort depreci
purchas account restructur charg one time charg
non-gaap ep exclud acquisit restructur one time relat charg
compani data secur llc estim reuter
mammographi busi monolith never divers set lever drive
growth breast busi beyond replac cycl mammographi
latter inning see opportun drive synergi recent complementari
acquisit upgrad older placement newer featur set new detector new softwar
smartcurv paddl allevi brevera suppli constraint expect told
everi reason believ holx breast health busi least keep pace forecast
market growth rate healthcar imag equip normal environ
period end expens share share sale sale ex acquir intang cash flowoper cash cash sale growth ex blood sale sale growth ex blood present conform adjust ep report companysourc secur llc estim compani report life scienc tool servic diagnost
price target
price target reflect enterpris valu use project level debt cash
ebitda ex option multipl discount median ev/ebitda multipl
devic peer group downsid risk overweight rate includ limit
follow factor first slowdown demand capit equip hospit would limit potenti
futur growth secondli extens cervic cancer screen interv would
neg impact downsid risk includ potenti increas competit molecular
diagnost acquisit target select integr
upsid risk overweight includ improv demand hospit addit expans
cervic cancer screen interv limit competit molecular diagnost well faster
expect margin improv across busi line could lead increas investor appetit stand
upsid risk rate
overweight rate reflect view compani growth opportun
diagnost breast health underappreci current level
inc medic equip suppli diagnost devic manufactur domin
market share billion world-wide mammographi market estim market share
million cervic cancer screen market estim share
compani oper four segment breast care revenu diagnost
revenu gyn surgic revenu skelet health revenu
compani gener billion corpor revenu million net profit septemb
